Tagrisso plus chemo recommended for approval in EU
3 June 2024 Tagrisso with the addition of chemotherapy recommended for approval inthe EU by CHMP for patients with EGFR-mutated advanced lung cancer Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care AstraZeneca's Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy has been recommended for approval in the European Union (EU) for 1st-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-